FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2314944440> ?p ?o ?g. }

• W2314944440 endingPage "162" @default.
• W2314944440 startingPage "155" @default.
• W2314944440 abstract "Anabolic-androgenic steroids (AAS) are nominated for clinical use to promote protein synthesis in many therapeutic conditions. However, the indiscriminate use of AAS is related to hazardous cardiac disturbances and oxidative stress. We designed a study to investigate whether prolonged treatment with high doses of stanozolol modifies the activities of some antioxidant enzymes in the heart in sedentary and trained rats and whether this treatment causes alterations of cardiovascular parameters. In addition, the effectiveness of melatonin as an antioxidant and as a modulator of the cardiovascular side effects of stanozolol (STA) treatment was analyzed.Thirty male Wistar rats were divided into the following six groups: sedentary (S), stanozolol sedentary (SS), stanozolol-melatonin sedentary (SMS), trained (T), stanozolol trained (ST) and stanozolol-melatonin trained (SMT). The stanozolol-treatment rats received 5 mg.kg(-1) by subcutaneous injection before each exercise session (5 d.wk(-1), i.e., 25 mg.kg(-1).wk(-1)), while control groups received only saline solution injection. The melatonin-treatment groups received intraperitoneal injections of melatonin (10 mg.kg(-1)), 5 d.wk(-1) for 6 wk. Electrocardiography, blood pressure and antioxidant enzyme activity measurements were performed at the end of the experimental period for cardiac function and molecular assessment.This is the first time that the in vivo effects of melatonin treatment on stanozolol-induced cardiovascular side effects have been studied. Stanozolol induced bradycardia and significantly increased cardiac superoxide dismutase and catalase activities. Trained stanozolol-treated rats experienced an increase in blood pressure and relative heart weight, and they developed left cardiac axis deviation. Although melatonin did not prevent cardiac hypertrophy in exercised stanozolol-treated animals, it maintained blood pressure and cardiac catalase activity, and it prevented stanozolol-induced cardiac electrical axis deviation.In conclusion, under our experimental conditions, chronic stanozolol administration induced mild cardiovascular side effects that were partly attenuated by melatonin treatment. However, these results showed that the combination of melatonin and exercise could minimize the stanozolol side effects in the cardiovascular system.Anabolik-androjenik steroidler (AAS) bir çok tedavi koşullarında protein sentezini artırmak üzere klinik kullanıma aday gösterilmektedir. Ancak, AAS’in gelişigüzel kullanımı tehlikeli kalp bozuklukları ve oksidatif stres ile ilişkilendirilmiştir. Bu çalışma, sedanter ve antrenmanlı sıçanlarda stanozololun yüksek dozda uzun süreli kullanımının kalpte bazı antioksidan enzim faaliyetleri değiştirip değiştirmediğini ve bu tedavinin kardiyovasküler parametrelerde değişikliklere neden olup olmayacağını araştırmak için tasarlanmıştır. Buna ek olarak, bir antioksidan ve stanozolol (STA) tedavisinin kardiyovasküler yan etkilerinin bir modülatörü olan melatoninin etkinliği analiz edilmiştir.Otuz erkek Wistar sıçan aşağıdaki altı gruba ayrılmıştır; sedanter (S), stanozolol sedanter (SS), stanozolol-melatonin sedanter (SMS), antrenmanlı(T), stanozolol- antrenmanlı (ST) ve stanozolol-melatonin antrenmanlı (SMT). Stanozolol ile muamele edilen sıçanlar her egzersiz seansından önce cilt altı enjeksiyonu ile 5 mg.kg−1 (5 d.wk−1, yani 25 mg.kg−1.wk−1) stanozolol alırken, kontrol grubuna sadece serum fizyolojik enjeksiyonu yapılmıştır. Melatonin grupları için intraperitonal enjeksiyon ile 5 d.wk−1 (10 mg.kg−1) melatonin 6 hafta uygulanmıştır. Kalp fonksiyonu ve moleküler değerlendirilme amacıyla EKG, kan basıncı ve antioksidan enzim aktivite ölçümleri deney sürecinin sonunda yapılmıştır.Bu çalışma ile ilk defa stanozolola bağlı kardiyovasküler yan etkilerin melatonin ile tedavisinin in vivo etkileri incelenmiştir. Stanozolol bradikardiye neden olmuş ve önemli ölçüde kalp süperoksit dismutaz ve katalaz aktivitelerini arttırmıştır. Antrenmanlı olup stanozolol ile tedavi edilen sıçanlarda kan basıncı ve bağıl kalp ağırlığında bir artış gözlemlenmiş ve sol kalp aks sapması gelişmiştir. Melatonin uygulanması, stanozolol ile tedavi edilen hayvanlarda kalp hipertrofisine engel olamamasına rağmen, kan basıncı ve kalp katalaz aktivitesini muhafaza etmiş ve stanozolola bağlı kalp elektrik aks sapmasını engellemeyi başarmıştır.Sonuç olarak, deneysel koşullar altında, kronik stanozolol uygulanması, melatonin tedavisi ile kısmen zayıflatılmış olan hafif kardiyovasküler yan etkilere neden olmaktadır. Ancak, bu sonuçlar melatonin ve egzersiz kombinasyonunun kardiyovasküler sistemde stanozololun yan etkilerini en aza indirelileceğini göstermektedir." @default.
• W2314944440 created "2016-06-24" @default.
• W2314944440 creator A5002964958 @default.
• W2314944440 creator A5053194572 @default.
• W2314944440 creator A5054673198 @default.
• W2314944440 creator A5057908947 @default.
• W2314944440 creator A5091526790 @default.
• W2314944440 date "2013-10-19" @default.
• W2314944440 modified "2023-10-16" @default.
• W2314944440 title "Melatonin Reduces Oxidative Stress and Cardiovascular Changes Induced by Stanozolol in Rats Exposed to Swimming Exercise" @default.
• W2314944440 cites W170491879 @default.
• W2314944440 cites W1936195323 @default.
• W2314944440 cites W1978152747 @default.
• W2314944440 cites W1992345790 @default.
• W2314944440 cites W2000605357 @default.
• W2314944440 cites W2008028901 @default.
• W2314944440 cites W2011988006 @default.
• W2314944440 cites W2013596638 @default.
• W2314944440 cites W2016520135 @default.
• W2314944440 cites W2031476500 @default.
• W2314944440 cites W2032919207 @default.
• W2314944440 cites W2039608727 @default.
• W2314944440 cites W2045399543 @default.
• W2314944440 cites W2051550526 @default.
• W2314944440 cites W2063306228 @default.
• W2314944440 cites W2082844092 @default.
• W2314944440 cites W2085273144 @default.
• W2314944440 cites W2088365929 @default.
• W2314944440 cites W2095067924 @default.
• W2314944440 cites W2098094265 @default.
• W2314944440 cites W2100020660 @default.
• W2314944440 cites W2109198113 @default.
• W2314944440 cites W2121640791 @default.
• W2314944440 cites W2127475498 @default.
• W2314944440 cites W2129695795 @default.
• W2314944440 cites W2162571194 @default.
• W2314944440 cites W2163690071 @default.
• W2314944440 cites W2165879274 @default.
• W2314944440 cites W2394780405 @default.
• W2314944440 cites W3039586246 @default.
• W2314944440 doi "https://doi.org/10.5152/eajm.2013.33" @default.
• W2314944440 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4261421" @default.
• W2314944440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25610273" @default.
• W2314944440 hasPublicationYear "2013" @default.
• W2314944440 type Work @default.
• W2314944440 sameAs 2314944440 @default.
• W2314944440 citedByCount "15" @default.
• W2314944440 countsByYear W23149444402016 @default.
• W2314944440 countsByYear W23149444402017 @default.
• W2314944440 countsByYear W23149444402018 @default.
• W2314944440 countsByYear W23149444402019 @default.
• W2314944440 countsByYear W23149444402020 @default.
• W2314944440 countsByYear W23149444402021 @default.
• W2314944440 countsByYear W23149444402022 @default.
• W2314944440 crossrefType "journal-article" @default.
• W2314944440 hasAuthorship W2314944440A5002964958 @default.
• W2314944440 hasAuthorship W2314944440A5053194572 @default.
• W2314944440 hasAuthorship W2314944440A5054673198 @default.
• W2314944440 hasAuthorship W2314944440A5057908947 @default.
• W2314944440 hasAuthorship W2314944440A5091526790 @default.
• W2314944440 hasBestOaLocation W23149444401 @default.
• W2314944440 hasConcept C1008401 @default.
• W2314944440 hasConcept C111566952 @default.
• W2314944440 hasConcept C126322002 @default.
• W2314944440 hasConcept C134018914 @default.
• W2314944440 hasConcept C185592680 @default.
• W2314944440 hasConcept C2776151105 @default.
• W2314944440 hasConcept C2777252815 @default.
• W2314944440 hasConcept C2778004101 @default.
• W2314944440 hasConcept C2778182776 @default.
• W2314944440 hasConcept C2778198053 @default.
• W2314944440 hasConcept C55493867 @default.
• W2314944440 hasConcept C71924100 @default.
• W2314944440 hasConceptScore W2314944440C1008401 @default.
• W2314944440 hasConceptScore W2314944440C111566952 @default.
• W2314944440 hasConceptScore W2314944440C126322002 @default.
• W2314944440 hasConceptScore W2314944440C134018914 @default.
• W2314944440 hasConceptScore W2314944440C185592680 @default.
• W2314944440 hasConceptScore W2314944440C2776151105 @default.
• W2314944440 hasConceptScore W2314944440C2777252815 @default.
• W2314944440 hasConceptScore W2314944440C2778004101 @default.
• W2314944440 hasConceptScore W2314944440C2778182776 @default.
• W2314944440 hasConceptScore W2314944440C2778198053 @default.
• W2314944440 hasConceptScore W2314944440C55493867 @default.
• W2314944440 hasConceptScore W2314944440C71924100 @default.
• W2314944440 hasIssue "3" @default.
• W2314944440 hasLocation W23149444401 @default.
• W2314944440 hasLocation W23149444402 @default.
• W2314944440 hasLocation W23149444403 @default.
• W2314944440 hasLocation W23149444404 @default.
• W2314944440 hasOpenAccess W2314944440 @default.
• W2314944440 hasPrimaryLocation W23149444401 @default.
• W2314944440 hasRelatedWork W1980207544 @default.
• W2314944440 hasRelatedWork W1993990081 @default.
• W2314944440 hasRelatedWork W2009692691 @default.
• W2314944440 hasRelatedWork W2017830665 @default.
• W2314944440 hasRelatedWork W2031318332 @default.
• W2314944440 hasRelatedWork W2038780749 @default.

• next